References
- STD facts - Human papillomavirus (HPV). centers for disease control and prevention. Published 2021 Jan 19. https://www.cdc.gov/std/hpv/stdfact-hpv.htm
- Nuns DD, Warts. Viruses, and cancer. Yale J Biol Med. 2015;88(2):127–129.
- Daley EM, Vamos CA, Thompson EL, et al. The feminization of HPV: how science, politics, economics and gender norms shaped U.S. HPV vaccine implementation. Papillomavirus Res. 2017;3:142–148.
- STD facts - HPV and men. centers for disease control and prevention. Published 2021 Jan 19. https://www.cdc.gov/std/hpv/stdfact-hpv-and-men.htm
- Products - Data Briefs - Number 354 - January 2020. Centers for disease control and prevention. Published 2020 Jan 29. https://www.cdc.gov/nchs/products/databriefs/db354.htm
- de Villiers E-M, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology. 2004;324(1):17–27.
- Palefsky J. Human papillomavirus infections: epidemiology and disease associations UpToDate. Published 2020 Dec 3. https://www.uptodate.com/contents/human-papillomavirus-infections-epidemiology-and-disease-associations
- Human papillomavirus (HPV) and cervical cancer. World Health Organization. cited 2021 Sept 5. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
- Carr J, Gyorfi T. Human papillomavirus. epidemiology, transmission, and pathogenesis. Clin Lab Med. 2000;20(2):235–255.
- Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–814.
- Han JJ, Beltran TH, Song JW, et al. Prevalence of genital human papillomavirus infection and human papillomavirus vaccination rates among US adult men: national health and nutrition examination survey (NHANES) 2013-2014. JAMA Oncol. 2017;3(6):810–816.
- How many cancers are linked with HPV each year? | CDC. centers for disease control and prevention. Published 2020 Sept 16. https://www.cdc.gov/cancer/hpv/statistics/cases.htm
- Cervical cancer - statistics. Cancer.Net. Published 2012 Jun 25. https://www.cancer.net/cancer-t%C3%BDpes/cervical-cancer/statistics
- Oral and oropharyngeal cancer - statistics. Cancer.Net. Published June 25, 2012. https://www.cancer.net/cancer-types/oral-and-oropharyngeal-cancer/statistics
- Gillison ML, Broutian T, Pickard RKL, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307(7):693–703.
- ASCO Post Staff. FDA approves nine-valent HPV vaccine for the prevention of certain HPV-related head and neck cancers - the ASCO post. Published 2020 Jul 10. https://ascopost.com/issues/july-10-2020/fda-approves-nine-valent-hpv-vaccine-for-the-prevention-of-certain-hpv-related-head-and-neck-cancers/
- Thomas Cox J, Palefsky J. Human papillomavirus vaccination. Oct 30 2020. https://www.uptodate.com/contents/human-papillomavirus-vaccination
- McQuillan G, Kruszon-Moran D, Markowitz L, et al. Products - Data Briefs - Number 280 - April 2017. Published 2019 Jun 6. https://www.cdc.gov/nchs/products/databriefs/db280.htm
- Rodríguez-Álvarez MI, Gómez-Urquiza JL, Husein-El Ahmed H, et al. Prevalence and risk factors of human papillomavirus in male patients: a systematic review and meta-analysis. Int J Environ Res Public Health. 2018;15(10):2210.
- Walker TY, Elam-Evans L, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years — United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68. DOI:10.15585/mmwr.mm6833a2.
- HPV vaccination rates low despite risks of related cancers. BlueCross BlueShield. https://www.bcbs.com/the-health-of-america/infographics/hpv-vaccination-rates-low-despite-risks-of-related-cancers
- Daniels V, Saxena K, Roberts C, et al. Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: a model based analysis. Vaccine. 2021;39(20):2731–2735.
- Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89(24):12180–12184.
- Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(5):F123–138. Suppl.
- Benard VB, Castle PE, Jenison SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol. 2017;3(6):833–837.
- Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444–1451.
- Drolet M, Bénard É, Boily M-C, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–580.
- Harder T, Wichmann O, Klug SJ, et al. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med. 2018;16(1):110.
- Villa A, Patton LL, Giuliano AR, et al. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: umbrella review of systematic reviews. J Am Dent Assoc. 2020;151(4):245–254.e24. 1939.
- Lin L, Macias Parra M, Sierra VY, et al. Long-term immunogenicity and safety of the AS04-adjuvanted human papillomavirus–16/18 vaccine in four- to six-year-old girls: three-year follow-up of a randomized phase III trial. Pediatr Infect Dis J. 2019;38(10):1061–1067.
- Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787–796.
- Link A, Zabel F, Schnetzler Y, et al. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol Baltim Md 1950. 2012;188(8):3724–3733.
- Lenz P, Thompson CD, Day PM, et al. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol Orlando Fla. 2003;106(3):231–237.
- The HPV vaccine: access and use in the U.S. KFF. Published 2021 Jul 12. https://www.kff.org/womens-health-policy/fact-sheet/the-hpv-vaccine-access-and-use-in-the-u-s/
- Merck to build $650m plant in nc to meet gardasil vaccine demand. economic development partnership of north Carolina. Published July 25, 2019. cited 2021 Sept 5. https://edpnc.com/merck-to-build-650m-plant-in-nc-to-meet-gardasil-vaccine-demand/
- Tanne JH. Trump’s call for essential drugs to be made in US threatens innovation, says trade group. BMJ. 2020;370:m3170.
- Dai T, Song J-S. Transforming COVID-19 vaccines into vaccination. Health Care Manag Sci. Published online 2021 Jun 16:1–5. doi:10.1007/s10729-021-09563-3
- How do U.S. healthcare resources compare to other countries? Peterson-KFF Health System Tracker. cited 2021 Sept 7. https://www.healthsystemtracker.org/chart-collection/u-s-health-care-resources-compare-countries/
- Whitney CG, Zhou F, Singleton J, et al. Benefits from immunization during the vaccines for children program era — United States, 1994–2013. MMWR Morb Mortal Wkly Rep. 2014;63(16):352–355.
- P-J L, Singleton JA, Rangel MC, et al. Influenza vaccination trends among adults 65 years or older in the United States, 1989-2002. Arch Intern Med. 2005;165(16):1849–1856.
- HPV vaccination: understanding HPV coverage | CDC. Centers for Disease Control and Prevention. Published 2021 Mar 22. cited 2021 Sept 5. https://www.cdc.gov/hpv/partners/outreach-hcp/hpv-coverage.html
- Offeddu V, Low MSF, Surendran S, et al. Acceptance and feasibility of school-based seasonal influenza vaccination in Singapore: a qualitative study. Vaccine. 2020;38(7):1834–1841.
- Bruni L, Saura-Lázaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021;144:106399.
- Chaw LL, Lim STW, Md Yussof SR. Human papillomavirus vaccine coverage among female students in Brunei Darussalam: results from the first 4 years of the national school-based vaccination programme. Heliyon. 2019;5(10):e02588.
- Bjerke RD, Laake I, Feiring B, et al. Time trends in HPV vaccination according to country background: a nationwide register-based study among girls in Norway. BMC Public Health. 2021;21(1):854.
- Tsu VD, LaMontagne DS, Atuhebwe P, et al. National implementation of HPV vaccination programs in low-resource countries: lessons, challenges, and future prospects. Prev Med. 2021;144:106335.
- Shinkafi-Bagudu Z. Global partnerships for HPV vaccine must look beyond national income. JCO Glob Oncol. 2020;6(6):1746–1748.
- Olson O, Berry C, Kumar N. Addressing parental vaccine hesitancy towards childhood vaccines in the United States: a systematic literature review of communication interventions and strategies. Vaccines (Basel). 2020;8(4):590.
- Uddin S, O’Conner K, Ashman J. Products - data briefs - Number 248 - May 2016. Published 2019 Jun 7. https://www.cdc.gov/nchs/products/databriefs/db248.htm
- Kovar CL, Pestaner M, Webb Corbett R, et al. HPV vaccine promotion: snapshot of two health departments during the COVID-19 pandemic. Public Health Nurs Boston Mass. 2021;38(5):715–719.
- Nguyen KH, Santibanez TA, Stokley S, et al. Parental vaccine hesitancy and its association with adolescent HPV vaccination. Vaccine. 2021;39(17):2416–2423.
- Sonawane K, Zhu Y, Montealegre JR, et al. Parental intent to initiate and complete the human papillomavirus vaccine series in the USA: a nationwide, cross-sectional survey. Lancet Public Health. 2020;5(9):e484–e492.
- Holman DM, Benard V, Roland KB, et al. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr. 2014;168(1):76–82.
- Tsui J, Vincent A, Anuforo B, et al. Understanding primary care physician perspectives on recommending HPV vaccination and addressing vaccine hesitancy. Hum Vaccines Immunother. 2021;17(7):1961–1967.
- Fu LY, Zimet GD, Latkin CA, et al. Associations of trust and healthcare provider advice with HPV vaccine acceptance among African American parents. Vaccine. 2017;35(5):802–807.
- Nan X, Daily K, Richards A, et al. The role of trust in health information from medical authorities in accepting the HPV vaccine among African American parents. Hum Vaccines Immunother. 2019;15(7–8):1723–1731.
- Eisenhauer L, Hansen BR, Pandian V. Strategies to improve human papillomavirus vaccination rates among adolescents in family practice settings in the United States: a systematic review. J Clin Nurs. 2021;30(3–4):341–356.
- Du J, Luo C, Shegog R, et al. Use of deep learning to analyze social media discussions about the human papillomavirus vaccine. JAMA Network Open. 2020;3(11):e2022025–e2022025.
- Rothman SM, Rothman DJ. Marketing and the HPV Vaccine—Reply. JAMA. 2009;302(24):2660–2661.
- Shah PD, Calo WA, Gilkey MB, et al. Easing human papillomavirus vaccine hesitancy: a communication experiment with U.S. parents. Am J Prev Med. 2021;61(1):88–95.
- Mayor E. Gender roles and traits in stress and health. Front Psychol. 2015;6:779.
- Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014;50(5):380–386.
- Petca A, Borislavschi A, Zvanca ME, et al. Non-sexual HPV transmission and role of vaccination for a better future (review). Exp Ther Med. 2020;20(6):186.
- Lindberg LD, Firestein L, Beavin C. Trends in U.S. adolescent sexual behavior and contraceptive use, 2006-2019. Contracept X. 2021;3:100064. Published 2021 Apr 8.
- McGinley KF, Hey W, Sussman DO, et al. Human papillomavirus testing in men. J Am Osteopath Assoc. 2011;111(3 Suppl 2):S26–28.
- Daniel-Ulloa J, Gilbert PA, Parker EA. Human papillomavirus vaccination in the United States: uneven uptake by gender, race/ethnicity, and sexual orientation. Am J Public Health. 2016;106(4):746–747.
- Your first gynecologic visit. ACOG. https://www.acog.org/en/womens-health/faqs/your-first-gynecologic-visit
- Osazuwa-Peters N, Massa ST, Simpson MC, et al. Survival of human papillomavirus-associated cancers: filling in the gaps. Cancer. 2018;124(1):18–20.
- Cervical Cancer Statistics | CDC. Centers for disease control and prevention. Published 2021 Jun 8. https://www.cdc.gov/cancer/cervical/statistics/index.htm
- Infectious Diseases Society of America. HPV vaccination rates remain critically low among younger adolescents in the U.S. ScienceDaily. https://www.sciencedaily.com/releases/2019/01/190117090506.htm
- Shew M, Shew ML, Bur AM. Otolaryngologists and their role in vaccination for prevention of HPV associated head & neck cancer. Hum Vaccines Immunother. 2018;15(7–8):1929–1934.
- Morais E, El Mouaddin N, Schuurman S, et al. Landscape assessment for gender neutral human papillomavirus vaccination recommendations including head and neck cancer burden data. Vaccine. Published online 2021 Aug 24;39(39):S0264-410X(21)01076–8.
- Deschler DG, Richmon JD, Khariwala SS, et al. The “new” head and neck cancer patient-young, nonsmoker, nondrinker, and HPV positive: evaluation. Otolaryngol–Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2014;151(3):375–380.
- Parsel SM, Barton BM, Beatty S, et al. Knowledge gaps among patients and providers in HPV-related oropharyngeal cancer: a systematic review. Otolaryngol Neck Surg. 2020;162(5):612–621.
- Suk R, Montealegre JR, Nemutlu GS, et al. Public knowledge of human papillomavirus and receipt of vaccination recommendations. JAMA Pediatr. 2019;173(11):1099–1102.
- Osazuwa-Peters N, Adjei Boakye E, Mohammed KA, et al. Not just a woman’s business! understanding men and women’s knowledge of HPV, the HPV vaccine, and HPV-associated cancers. Prev Med. 2017;99:299–304.
- Gerend MA, Shepherd MA, Lustria MLA, et al. Predictors of provider recommendation for HPV vaccine among young adult men and women: findings from a cross-sectional survey. Sex Transm Infect. 2016;92(2):104–107.
- Gilkey MB, McRee A-L. Provider communication about HPV vaccination: a systematic review. Hum Vaccines Immunother. 2016;12(6):1454–1468.
- Ecarnot F, Crepaldi G, Juvin P, et al. Pharmacy-based interventions to increase vaccine uptake: report of a multidisciplinary stakeholders meeting. BMC Public Health. 2019;19(1):1698.
- Kuter BJ, Garland SM, Giuliano AR, et al. Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: what’s ongoing, what’s needed. Prev Med. 2021;144:106321.
- Ventola CL. Immunization in the United States: recommendations, barriers, and measures to improve compliance. Pharm Ther. 2016;41(7):426–436.
- Adolescent vaccination rates in America. BlueCross BlueShield. Published February 13, 2018. https://www.bcbs.com/the-health-of-america/reports/adolescent-vaccination-rates-in-america
- HPV Vaccination in Africa-. New delivery schedules alias the HANDS HPV vaccine trial - full text view - clinicalTrials.gov. U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT03832049
- Beavis A, Krakow M, Levinson K, et al. Reasons for lack of HPV vaccine initiation in NIS-teen over time: shifting the focus from gender and sexuality to necessity and safety. J Adolesc Health. 2018;63(5):652–656.
- Brouwer AF, Delinger RL, Eisenberg MC, et al. HPV vaccination has not increased sexual activity or accelerated sexual debut in a college-aged cohort of men and women. BMC Public Health. 2019;19(1):821.
- Kjaer SK, Nygård M, Sundström K, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine. 2020;23:100401. Published 2020 Jun 20.
- Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858–6867.